Innovating for the safety
of women and babies
during childbirth.
A direct means to evaluate fetal oxygenation during labor.
Raydiant Oximetry
is revolutionizing
labor & delivery
In developing Lumerah™, a noninvasive sensor technology that directly measures fetal oxygen levels, Raydiant Oximetry aims to profoundly reduce the rising mortality and morbidity rates among mothers and babies during childbirth.
For the past 50 years, electronic fetal monitoring has been associated with a 6-fold increase in cesarean delivery in the US without any evidence that it reduces the rate of neonatal neurologic injury, stillbirth or cerebral palsy. Obstetrical providers need a more reliable tool to evaluate fetal oxygenation.
”The U.S. has the worst rate of maternal deaths
in the developed world.”
NINA MARTIN, NPR
OUR INNOVATION
A technological transformation in maternal care
In a bid to provide healthcare professionals with a more accurate method to to evaluate fetal oxygenation, Raydiant Oximetry is developing Lumerah™, a noninvasive fetal pulse oximeter.
Accurate
Preclinical trials indicate that Lumerah™ significantly improves sensitivity and specificity when detecting fetal distress.
Risk Stratification
Lumerah™ grants healthcare professionals greater insight and confidence when making decisions during labor and delivery.
Breakthrough Status
The FDA has already assigned Lumerah™ ‘Breakthrough Device’ status in order to fast-track its market approval.
Grants, Awards, and Partners
Latest News
Raydiant Oximetry Secures $1 Million Grant to Advance Fetal Monitoring Technology
Raydiant Oximetry, Inc., a clinical-stage medical device company developing innovations to keep mothers and babies safe during childbirth, has announced the receipt of a $1 million grant from the Bill & Melinda Gates Foundation.
Raydiant Oximetry Kicks Off Series B Financing Round with an Investment from March of Dimes
Raydiant Oximetry, Inc., announced that it has received an investment from the March of Dimes Innovation Fund to kick off its Series B financing round.
AngelMD Portfolio Company Raydiant Oximetry Awarded FDA Breakthrough Device Status
The accelerated path to approval through the breakthrough device program will enable better care to millions of mothers and babies during childbirth.
Fogarty Innovation Graduate Raydiant Oximetry Raises $5 Million in Oversubscribed Series A2 Financing Round to Support Clinical Study
The funding was led by Avestria Ventures, which invests in early-stage women’s health companies, and syndicated by KOFA Healthcare, V-Capital, Band of Angels, FemHealth Ventures, RHIA Ventures, SteelSky Ventures and Tri-Valley Ventures.
Raydiant Oximetry Receives $3 Million Grant to Advance Its Innovative Technology
Raydiant Oximetry, a Fogarty Innovation graduate, is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth and recently received a grant from the government of Ireland for approximately $3 million.
Raydiant Oximetry Raises Series A Funding; Graduates from Fogarty Institute.
Raydiant Oximetry, a Fogarty Institute company that is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth, has closed a $5.6 million Series A funding round led by VCapital.
Get in touch
Have an inquiry? Send us a message and we’ll be in touch as soon as possible.